{
    "organizations": [],
    "uuid": "4edc89aefa41f7d02b9206a5538a57d6e76cb486",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-lysogene-had-cash-and-cash-equival/brief-lysogene-had-cash-and-cash-equivalent-of-eur-9-9-million-on-march-31-idUSFWN1RT03D",
    "ord_in_thread": 0,
    "title": "BRIEF-Lysogene Had Cash And Cash Equivalent Of EUR 9.9 Million On March 31",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 16 (Reuters) - LYSOGENE SA:\n* LYSOGENE REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE\n* AS OF MARCH 31, 2018, CASH AND CASH EQUIVALENT AMOUNTED TO EUR 9.9 MILLION\n* LYSOGENE DID NOT GENERATE REVENUES DURING Q1 2018 * LYS-SAF302 IN MPS IIIA: PIVOTAL CLINICAL TRIAL NOW SCHEDULED TO START IN H2 OF 2018\n* LYS-GM101 IND-ENABLING PRECLINICAL STUDY PROGRAM IN GM1: INTENDS TO REPORT LONG-TERM RESULTS IN H2 OF 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-16T13:52:00.000+03:00",
    "crawled": "2018-04-17T12:40:38.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "lysogene",
        "sa",
        "lysogene",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "business",
        "update",
        "march",
        "cash",
        "cash",
        "equivalent",
        "amounted",
        "eur",
        "million",
        "lysogene",
        "generate",
        "revenue",
        "q1",
        "mp",
        "iiia",
        "pivotal",
        "clinical",
        "trial",
        "scheduled",
        "start",
        "h2",
        "preclinical",
        "study",
        "program",
        "gm1",
        "intends",
        "report",
        "result",
        "h2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}